Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Colon Cancer
Genomic Health Announces Commencement of QUASAR Clinical Validation Study for Oncotype DX(R) Colon Cancer Assay
January 27th, 2009
Genomic Health, Inc. (NASDAQ:GHDX) announced that it has initiated an independent clinical validation study for its 18-gene Oncotype DX(R) colon cancer assay. Utilizing more than 1,200 patient samples from the landmark QUASAR trial, the validation study will use prospectively defined endpoints to assess the clinical utility of the Oncotype DX colon cancer assay to predict likelihood of recurrence for stage II colon cancer patients treated with surgery alone and the magnitude of treatment benefit with chemotherapy following surgery. Results from the study are expected to be reported in the second half of 2009. Stage II colon cancer (also known as Dukes' Stage B) affects...
Source: Cancer Weekly (2009-01-27)
|
